The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland
Abstract
Background: Clozapine can cause reversible agranulocytosis and neutropenia. This study documents the occurrence of blood dyscrasias and identifies predisposing risk factors. Method: An analysis was made of the haematological, demographic, and dosage data from a central database on 6316 patients receiving clozapine over four and a half years in the UK and Ireland. Results: During the study period 2.9% of the patients developed neutropenia and 0.8% developed agranulocytosis. The peak incidence of both disorders was in the first 6–18 weeks of treatment. Fatal agranulocytosis occurred in 0.03% of patients. After the first year of treatment the incidence of agranulocytosis significantly decreased to the order noted with some phenothiazines. Conclusions: The use of a patient monitoring service kept the haematological risks associated with using clozapine within acceptable limits, particularly in view of the benefits of this medication in treatment-resistant schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clozapine for the Treatment-Resistant Schizophrenic: A Double-blind Comparison With Chlorpromazine
Kane, J. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800330013001 · Cited by 4,156
Clozapine-induced agranulocytosis. incidence and risk factors in the united states
Alvir, J. M. J., Lieberman, J. A., Safferman, A. Z., Schwimmer, J. L., & Schaaf, J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199307153290303 · Cited by 967
Self-citationThe Effects of Clozapine on Tardive Dyskinesia
Lieberman, J. A., Saltz, B. L., Johns, C. A., Pollack, S., Borenstein, M., & Kane, J. (1991) · British Journal of Psychiatry · doi:10.1192/bjp.158.4.503 · Cited by 302
Self-citationMeltzer, H. Y., Bastani, B., Kwon, K. Y., Ramirez, L. F., Burnett, S., & Sharpe, J. (1989) · Psychopharmacology · doi:10.1007/bf00442563 · Cited by 271
Dimensions of Outcome with Clozapine
Meltzer, H. Y. (1992) · British Journal of Psychiatry · doi:10.1192/s000712500029692x · Cited by 252
Leukopenia, Neutropenia, and Reduced Hemoglobin Levels in Healthy American Blacks
Reed, W. W. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400030063011 · Cited by 129
Pisciotta, V. (1978) · Drugs · doi:10.2165/00003495-197815020-00003 · Cited by 129
Clozapine, negative symptoms, and extrapyramidal side effects.
Kane, J. M., Safferman, A. Z., Pollack, S. Z., et al. (1994) · PubMed · Cited by 29
Cited by
Tolerability of Atypical Antipsychotics
Stanniland, C., & Taylor, D. (2000) · Drug Safety · doi:10.2165/00002018-200022030-00004 · Cited by 303
Active monitoring of 12760 clozapine recipients in the UK and Ireland: Beyond pharmacovigilance
Munro, J., O'Sullivan, D., Andrews, C., Arana, A., Mortimer, A., & Kerwin, R. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.175.6.576 · Cited by 285
Self-citationDrug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance
Zhou, S., Chan, E., Duan, W., Huang, M., & Chen, Y.-Z. (2005) · Drug Metabolism Reviews · doi:10.1081/dmr-200028812 · Cited by 274
Haematological toxicity of drugs used in psychiatry
Flanagan, R. J., & Dunk, L. (2008) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.917 · Cited by 236
An update of safety of clinically used atypical antipsychotics
Orsolini, L., Tomasetti, C., Valchera, A., Vecchiotti, R., Matarazzo, I., Vellante, F., Iasevoli, F., Buonaguro, E. F., Fornaro, M., Fiengo, A. L. C., et al. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1201475 · Cited by 135
Metadata
- Authors
- Atkin, K., Kendall, F., Gould, D., Freeman, H., Lieberman, J., & O'Sullivan, D.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1996-10
- Volume
- 169
- Issue
- 4
- Pages
- 483-488
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W1987240985
- Cited by
- 293
- References
- 8
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland. https://app.cochat.ai/papers/10.1192/bjp.169.4.483
- The paper
- Atkin, K., Kendall, F., Gould, D., Freeman, H., Lieberman, J., & O'Sullivan, D. (1996). Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland. British Journal of Psychiatry. https://doi.org/10.1192/bjp.169.4.483
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.